Bausch Health Companies Inc Dossier - Source-backed chat

Bausch Health Companies Inc

BHCNYSE

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)0.62

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $5.83Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $2.2B

Enterprise Value $21.1B

Shares Outstanding 375.4M diluted

Moat Rating None

Next Earnings Date29 Oct 2026

Last ex-dividend10 Nov 2010

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Bausch Health Companies Inc. (BHC) continues to deliver solid operational performance, marking its twelfth consecutive quarter of year-over-year revenue and adjusted EBITDA growth in Q1 2026. This growth is driven by strong performance in its Salix (gastroenterology) and Solta Medical (aesthetics) segments. However, the investment case is heavily constrained by a massive debt load of approximately $20.8 billion, which limits financial flexibility and complicates the full separation of its highly valued Bausch + Lomb eye health business. Furthermore, the company's primary revenue driver, Xifaxan, faces looming patent litigation and potential generic entry as early as January 1, 2028. While operational execution remains disciplined under CEO Thomas J. Appio, the structural overhang of leverage and patent cliffs warrants a cautious Hold recommendation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.50

Mean target$7.50

High · most bullish analyst$9.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

An unfavorable legal ruling leads to early generic entry for Xifaxan before 2028, severely eroding the company's cash flow and EBITDA. High interest rates increase refinancing costs on the $20.8 billion debt load, raising solvency concerns and preventing the separation of Bausch + Lomb.

Base CaseCentral scenario

The company successfully maintains mid-single-digit organic revenue growth driven by Salix and Solta Medical, while managing its debt maturities through opportunistic refinancings. The full separation of Bausch + Lomb remains delayed but progress is made on reducing net debt. Xifaxan exclusivity is maintained through 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Twelve consecutive quarters of year-over-year revenue and adjusted EBITDA growth as of Q1 2026, demonstrating strong underlying operational execution.
Robust performance in the Salix segment (gastroenterology) and Solta Medical, which grew 51% in Q1 2026 aided by the Shibo acquisition in China.
Substantial ownership stake (approximately 88%) in Bausch + Lomb Corporation, representing significant latent value once structural separation hurdles are cleared.

Key Investment Risks

Extremely high leverage with approximately $20.8 billion in total debt against a market capitalization of under $2 billion.
Looming loss of exclusivity (LOE) for Xifaxan, which represents a significant portion of the company's high-margin pharmaceutical revenues.
Setbacks in clinical development, such as the failure of the RED-C Phase 3 trials to meet primary endpoints in early 2026.

Thesis Invalidation Triggers

Early generic entry of Xifaxan prior to the expected 2028 timeline.
Inability to refinance upcoming debt maturities on sustainable terms.
A material decline in Solta Medical's growth momentum in key Asian markets.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.